Dr. Jessica M. Schuster

Claim this profile

William S Middleton VA Medical Center

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
12 drugs studied

Area of expertise

1

Lung Cancer

Jessica M. Schuster has run 2 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
ALK positive
2

Non-Small Cell Lung Cancer

Jessica M. Schuster has run 1 trial for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage I
Stage II

Affiliated Hospitals

Image of trial facility.

William S Middleton VA Medical Center

Clinical Trials Jessica M. Schuster is currently running

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.

Recruiting

2 awards

Phase 3

More about Jessica M. Schuster

Clinical Trial Related

5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Jessica M. Schuster has experience with

  • Stereotactic Body Radiation Therapy
  • Cisplatin
  • Atezolizumab
  • Radiation Therapy
  • Apalutamide
  • Targeted Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Jessica M. Schuster specialize in?

Is Jessica M. Schuster currently recruiting for clinical trials?

Are there any treatments that Jessica M. Schuster has studied deeply?

What is the best way to schedule an appointment with Jessica M. Schuster?

What is the office address of Jessica M. Schuster?

Is there any support for travel costs?